Literature DB >> 25263597

Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease.

Ranjan Batra1, Konstantinos Charizanis1, Mini Manchanda1, Apoorva Mohan1, Moyi Li1, Dustin J Finn1, Marianne Goodwin1, Chaolin Zhang2, Krzysztof Sobczak3, Charles A Thornton4, Maurice S Swanson5.   

Abstract

Inhibition of muscleblind-like (MBNL) activity due to sequestration by microsatellite expansion RNAs is a major pathogenic event in the RNA-mediated disease myotonic dystrophy (DM). Although MBNL1 and MBNL2 bind to nascent transcripts to regulate alternative splicing during muscle and brain development, another major binding site for the MBNL protein family is the 3' untranslated region of target RNAs. Here, we report that depletion of Mbnl proteins in mouse embryo fibroblasts leads to misregulation of thousands of alternative polyadenylation events. HITS-CLIP and minigene reporter analyses indicate that these polyadenylation switches are a direct consequence of MBNL binding to target RNAs. Misregulated alternative polyadenylation also occurs in skeletal muscle in a mouse polyCUG model and human DM, resulting in the persistence of neonatal polyadenylation patterns. These findings reveal an additional developmental function for MBNL proteins and demonstrate that DM is characterized by misregulation of pre-mRNA processing at multiple levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25263597      PMCID: PMC4224598          DOI: 10.1016/j.molcel.2014.08.027

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  41 in total

1.  Progressive lengthening of 3' untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development.

Authors:  Zhe Ji; Ju Youn Lee; Zhenhua Pan; Bingjun Jiang; Bin Tian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

Review 2.  Alternative splicing: a pivotal step between eukaryotic transcription and translation.

Authors:  Alberto R Kornblihtt; Ignacio E Schor; Mariano Alló; Gwendal Dujardin; Ezequiel Petrillo; Manuel J Muñoz
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-06       Impact factor: 94.444

Review 3.  Pre-mRNA splicing in disease and therapeutics.

Authors:  Ravi K Singh; Thomas A Cooper
Journal:  Trends Mol Med       Date:  2012-07-18       Impact factor: 11.951

4.  Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise.

Authors:  Christopher M Chamberlain; Laura P W Ranum
Journal:  Hum Mol Genet       Date:  2012-07-30       Impact factor: 6.150

5.  Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.

Authors:  Eric T Wang; Neal A L Cody; Sonali Jog; Michela Biancolella; Thomas T Wang; Daniel J Treacy; Shujun Luo; Gary P Schroth; David E Housman; Sita Reddy; Eric Lécuyer; Christopher B Burge
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

6.  Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.

Authors:  Konstantinos Charizanis; Kuang-Yung Lee; Ranjan Batra; Marianne Goodwin; Chaolin Zhang; Yuan Yuan; Lily Shiue; Melissa Cline; Marina M Scotti; Guangbin Xia; Ashok Kumar; Tetsuo Ashizawa; H Brent Clark; Takashi Kimura; Masanori P Takahashi; Harutoshi Fujimura; Kenji Jinnai; Hiroo Yoshikawa; Mário Gomes-Pereira; Geneviève Gourdon; Noriaki Sakai; Seiji Nishino; Thomas C Foster; Manuel Ares; Robert B Darnell; Maurice S Swanson
Journal:  Neuron       Date:  2012-08-09       Impact factor: 17.173

7.  Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation.

Authors:  Chengguo Yao; Jacob Biesinger; Ji Wan; Lingjie Weng; Yi Xing; Xiaohui Xie; Yongsheng Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

8.  Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation.

Authors:  Eleonora de Klerk; Andrea Venema; S Yahya Anvar; Jelle J Goeman; Ouhua Hu; Capucine Trollet; George Dickson; Johan T den Dunnen; Silvère M van der Maarel; Vered Raz; Peter A C 't Hoen
Journal:  Nucleic Acids Res       Date:  2012-07-06       Impact factor: 16.971

9.  A quantitative atlas of polyadenylation in five mammals.

Authors:  Adnan Derti; Philip Garrett-Engele; Kenzie D Macisaac; Richard C Stevens; Shreedharan Sriram; Ronghua Chen; Carol A Rohl; Jason M Johnson; Tomas Babak
Journal:  Genome Res       Date:  2012-03-27       Impact factor: 9.043

10.  ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.

Authors:  Eveline S Arnold; Shuo-Chien Ling; Stephanie C Huelga; Clotilde Lagier-Tourenne; Magdalini Polymenidou; Dara Ditsworth; Holly B Kordasiewicz; Melissa McAlonis-Downes; Oleksandr Platoshyn; Philippe A Parone; Sandrine Da Cruz; Kevin M Clutario; Debbie Swing; Lino Tessarollo; Martin Marsala; Christopher E Shaw; Gene W Yeo; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more
  139 in total

1.  Distal Alternative Last Exons Localize mRNAs to Neural Projections.

Authors:  J Matthew Taliaferro; Marina Vidaki; Ruan Oliveira; Sara Olson; Lijun Zhan; Tanvi Saxena; Eric T Wang; Brenton R Graveley; Frank B Gertler; Maurice S Swanson; Christopher B Burge
Journal:  Mol Cell       Date:  2016-02-18       Impact factor: 17.970

2.  Global insights into alternative polyadenylation regulation.

Authors:  Ranjan Batra; Mini Manchanda; Maurice S Swanson
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 3.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

4.  Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

Authors:  Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

5.  Mechanistic determinants of MBNL activity.

Authors:  Łukasz J Sznajder; Michał Michalak; Katarzyna Taylor; Piotr Cywoniuk; Michał Kabza; Agnieszka Wojtkowiak-Szlachcic; Magdalena Matłoka; Patryk Konieczny; Krzysztof Sobczak
Journal:  Nucleic Acids Res       Date:  2016-10-12       Impact factor: 16.971

Review 6.  Molecular networks underlying myofibroblast fate and fibrosis.

Authors:  April Stempien-Otero; Deok-Ho Kim; Jennifer Davis
Journal:  J Mol Cell Cardiol       Date:  2016-05-07       Impact factor: 5.000

Review 7.  RNA-binding proteins in neurodegeneration: Seq and you shall receive.

Authors:  Julia K Nussbacher; Ranjan Batra; Clotilde Lagier-Tourenne; Gene W Yeo
Journal:  Trends Neurosci       Date:  2015-03-09       Impact factor: 13.837

Review 8.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

9.  Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.

Authors:  Samuel T Carrell; Ellie M Carrell; David Auerbach; Sanjay K Pandey; C Frank Bennett; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2016-08-13       Impact factor: 6.150

10.  MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.

Authors:  Marianne Goodwin; Apoorva Mohan; Ranjan Batra; Kuang-Yung Lee; Konstantinos Charizanis; Francisco José Fernández Gómez; Sabiha Eddarkaoui; Nicolas Sergeant; Luc Buée; Takashi Kimura; H Brent Clark; Joline Dalton; Kenji Takamura; Sebastien M Weyn-Vanhentenryck; Chaolin Zhang; Tammy Reid; Laura P W Ranum; John W Day; Maurice S Swanson
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.